

Part I

₹ in lacs

Particulars	Quarter Ended			Year Ended
	30.06.2015	31.03.2015	30.06.2014	31.03.2015
	(Unaudited)			(Audited)
<b>1 Income from operations</b>				
a Net sales / income from operations (net of excise duty)	9,451.12	9,633.24	8,133.36	36,730.33
b Other operating income	79.07	157.04	145.59	638.50
<b>Total income from operations (net)</b>	<b>9,530.19</b>	<b>9,790.28</b>	<b>8,278.95</b>	<b>37,368.83</b>
<b>2 Expenses</b>				
a Cost of materials consumed	3,442.24	3,314.99	2,756.18	13,127.13
b Purchases of stock-in-trade	143.77	107.42	155.64	652.53
c Changes in inventories of finished goods, work-in-progress and stock-in-trade	66.14	284.91	26.85	(306.83)
d Employee benefits expense	1,571.06	1,478.94	1,372.51	6,030.00
e Depreciation and amortisation expense	517.69	482.48	400.64	1,808.99
f Other expenses	2,505.69	2,672.65	2,040.40	9,602.68
<b>Total expenses</b>	<b>8,246.59</b>	<b>8,341.39</b>	<b>6,752.22</b>	<b>30,914.50</b>
<b>3 Profit from operations before other income, finance costs and exceptional items (1-2)</b>	<b>1,283.60</b>	<b>1,448.89</b>	<b>1,526.73</b>	<b>6,454.33</b>
4 Other income	171.17	123.41	49.67	822.14
<b>5 Profit from ordinary activities before finance costs and exceptional items (3 + 4)</b>	<b>1,454.77</b>	<b>1,572.30</b>	<b>1,576.40</b>	<b>7,276.47</b>
6 Finance costs	199.49	174.13	194.37	822.65
7 Profit from ordinary activities after finance costs but before exceptional items (5 - 6)	<b>1,255.28</b>	<b>1,398.17</b>	<b>1,382.03</b>	<b>6,453.82</b>
8 Exceptional items	-	-	-	1,957.80
<b>9 Profit from ordinary activities before tax (7 + 8)</b>	<b>1,255.28</b>	<b>1,398.17</b>	<b>1,382.03</b>	<b>8,411.62</b>
10 Tax expense	279.90	187.80	411.19	2,309.90
<b>11 Net Profit from ordinary activities after tax (9 - 10)</b>	<b>975.38</b>	<b>1,210.37</b>	<b>970.84</b>	<b>6,101.72</b>
12 Extraordinary items	-	-	-	-
<b>13 Net Profit for the period (11 + 12)</b>	<b>975.38</b>	<b>1,210.37</b>	<b>970.84</b>	<b>6,101.72</b>
14 Paid-up equity share capital (Face Value of ₹ 5 each)	2,205.67	2,205.67	2,204.07	2,205.67
15 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				16,991.29
16 Earnings per share (before extraordinary items) (Quarterly not annualised and yearly annualised) :				
Basic ( ₹ )	2.21	2.74	2.20	13.83
Diluted ( ₹ )	2.21	2.74	2.20	13.83

Part II - Select information for the Quarter ended June 30, 2015

A PARTICULARS OF SHAREHOLDING				
1 Public shareholding				
Number of shares	226,62,564	226,62,564	226,30,620	226,62,564
Percentage of shareholding	51.37%	51.37%	51.34%	51.37%
2 Promoters and Promoter Group Shareholding				
a) Pledged / Encumbered				
Number of shares	-	-	-	-
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-
Percentage of shares (as a % of the total share capital of the company)	-	-	-	-
b) Non - encumbered				
Number of shares	214,50,876	214,50,876	214,50,876	214,50,876
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%
Percentage of shares (as a % of the total share capital of the company)	48.63%	48.63%	48.66%	48.63%
<b>B Investor Complaints</b>				
Pending at the beginning of the quarter	Nil			
Received during the quarter	Nil			
Disposed of during the quarter	Nil			
Remaining unresolved at the end of the quarter	Nil			



*Munarch*  
POLY MEDICURE LTD.

**Notes:**

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 31<sup>st</sup> July 2015.
- 2 The figure for the quarter ended March 2015 are the balancing figures between the audited figures in respect of the full financial year and the published figures for nine months ended 31<sup>st</sup> December 2014.
- 3 Earning per share for the previous quarter ended 30th June 2014 have been adjusted pursuant to sub division of equity share from ₹ 10 each to ₹ 5 each fully paid up for comparison purposes.
- 4 The Company is primarily engaged in the business of manufacture and sale of "Medical Devices" and, hence, there is no reportable segments as per Accounting Standard-17 issued by ICAI.
- 5 The statutory Auditors have carried out the limited review of the above results.
- 6 The figures for the corresponding periods have been regrouped / rearranged, wherever necessary, to make them comparable.

**Place : New Delhi**  
**Date : 31.07.2015**



*Himanshu Baid*

**Himanshu Baid**  
**Managing Director**



# DOOGAR & ASSOCIATES

Chartered Accountants

## LIMITED REVIEW REPORT

### **The Board of Directors**

Poly Medicure Limited  
232B, 3<sup>rd</sup> Floor, Okhla Industrial Estate,  
Phase III, New Delhi – 110 020.

Dear Sirs,


1. We have reviewed the accompanying statement of unaudited financial results of Poly Medicure Limited (the 'Company') for the quarter ended June 30<sup>th</sup>, 2015 except for the disclosures regarding "Public Shareholding" and "Promoters and Promoters Group Shareholding" which have been traced from disclosures made by the Management and have not been audited by us. These unaudited financial statements are the responsibility of the Company's Management and have been approved by the Board of Directors. Our responsibility is to issue a report on these unaudited financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results of the company prepared in accordance with applicable accounting standards notified under section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with the Stock Exchanges, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: New Delhi  
Date: 31/07/2015.

**For Doogar & Associates**

Chartered Accountants

Reg. No.000561

  
(M. S. Agarwal)

Partner

M. No. 86580

